STAT+: Gene therapy’s long-debated cancer risk materializes
The need-to-know this morning Vir Biotechnology said monthly injections of two experimental medicines reduced hepatitis D virus to undetectable levels in 44% of patients compared to none of the patients who received delayed treatment with the same regimen.
Key points
- The tumors possibly connected to pediatric gene therapies make me sad.
- Continue to STAT+ to read the full story….
- Argenx is acquiring privately held Unnatural Products, a medicinal chemistry company that specializes in the discovery of protein-based drugs.
Why two heart trials should puncture AI drug discovery enthusiasm Before anyone promises that AI will cure every disease, consider what happened the last time a shiny new tool was supposed to make drug development more predictable.
Additional details
- Roivant said Lisraya generated $31 million in sales in the five weeks since it was approved to treat dermatomyositis.
- At the American Heart Association meeting, two big trials came up empty.
- Want to stay on top of the science and politics driving biotech today?
- The result achieved the primary goal of a Phase 3 study.
- Sign up to get our biotech newsletter in your inbox.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.